Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.772 GBX | -3.50% | -3.50% | -9.18% |
Apr. 25 | N4 Pharma strikes partnership deal for intracellular delivery | AN |
Apr. 23 | N4 Pharma loss widens but "great optimism" remains | AN |
Sales 2022 | - | Sales 2023 | 1.95K 2.48K | Capitalization | 2.28M 2.9M |
---|---|---|---|---|---|
Net income 2022 | -1M -1.27M | Net income 2023 | -1M -1.27M | EV / Sales 2022 | - |
Net cash position 2022 | 1.92M 2.43M | Net cash position 2023 | 1.03M 1.3M | EV / Sales 2023 | 644 x |
P/E ratio 2022 |
-3.35
x | P/E ratio 2023 |
-1.63
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 77.72% |
Latest transcript on N4 Pharma Plc
1 day | -3.50% | ||
1 week | -3.50% | ||
Current month | -3.50% | ||
1 month | -6.42% | ||
3 months | +2.93% | ||
6 months | -0.39% | ||
Current year | -9.18% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 59 | 13-12-31 | |
David Templeton
CTO | Chief Tech/Sci/R&D Officer | - | 17-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 46 | 20-07-13 | |
Founder | 59 | 13-12-31 | |
Chris Britten
CHM | Chairman | - | 19-05-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 0.772 | -3.50% | 17 019 |
24-05-16 | 0.8 | 0.00% | 14,538 |
24-05-15 | 0.8 | 0.00% | 142,520 |
24-05-14 | 0.8 | 0.00% | 26,527 |
24-05-13 | 0.8 | 0.00% | 68,233 |
Delayed Quote London S.E., May 17, 2024 at 03:48 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-9.18% | 2.72M | |
+32.09% | 694B | |
+29.29% | 593B | |
-1.68% | 371B | |
+19.81% | 331B | |
+6.45% | 290B | |
+14.08% | 239B | |
-3.15% | 209B | |
+9.97% | 209B | |
+8.03% | 169B |
- Stock Market
- Equities
- ONZ Stock